Audentes Therapeutics is conducting a survey to gather important data related to the Quality of Life & Economic Impacts of XLMTM. The results of this survey will be published and shared with the XLMTM community, and could be shared with health policy makers and insurance companies to support patient access to future treatments. Initially the survey is live for US-based families, with UK and German versions coming soon. They have asked us, along with other patient advocacy organizations, to help share the following information:
Family and Caregiver Economic and Quality of Life Impact of XLMTM Study
Audentes Therapeutics, Inc. recently hired Precision Xtract, an independent consulting company specializing in conducting health outcomes studies, to field a non-interventional (meaning no investigational product is given) study of parents and caregivers of children with XLMTM. This study will collect information about the experiences of XLMTM families and other caregivers in caring for XLMTM patients via an anonymous, internet-based survey. Parents and caregivers of XLMTM patients that are living or that have passed are eligible to participate. The goal of this study is to create a more thorough understanding of the quality of life and economic impact of XLMTM on families and caregivers. Upon completion of the study, the results will be published and shared with the XLMTM community. In addition, summary results could be shared in the future with health policy makers and insurance companies to support patient access to potential treatments.
If you are interested in participating, please follow the link at the bottom of this page. More detailed information about the study, who is eligible to complete the survey and important privacy and consent information are available via this link.
Your privacy, and that of your child, is of the highest consideration for the conduct of this study and the sharing of its results. At no time will your child’s identity, your identity, or any individual patient or caregiver information be shared publicly, or in any way that can be directly linked to you or your child.
Since you all lead very busy lives, the survey is designed so that it may be started and paused so that it may be completed in multiple sessions, if desired. The entire survey is intended to take no more than one hour in total time to complete. Your support of this study is much appreciated and will provide important insights on the quality of life and economic aspects of XLMTM.
CLICK HERE FOR LINK TO SURVEY
In September, Erin and Marie (and Myo!) traveled to San Diego for the 2019 RARE Patient Advocacy Summit put on by Global Genes. We represented our MTM-CNM community and gave a Poster Presentation entitled "Power of Patient-Professional Collaborative Conferences", sharing some unique features of our Conference model, and helping to inspire others interested in similar collaborative efforts. Put simply, our conference is not just about families or just about research. It is about bringing all together - families, researchers, medical professionals, pharma industry - and creating an experience that is truly greater than the sum of its parts and moves our community forward together. Check out the poster below!
Can't wait to see you all soon in St. Lou! Here you will find the detailed agenda for the Conference (you will also get a copy in your program book upon checking in at the Community Connections reception on Friday at 2PM).
For more information about the Conference, click here. Any questions, please email email@example.com
By Mark Ward, MTM-CNM Family Connection
You may have seen some news recently about Zolgensma, a gene therapy that just got approval from the FDA for use in patients with Type 1 Spinal Muscular Atrophy (SMA). It’s disappointing, but not surprising, that most of the headlines are exclaiming the cost of the treatment ($2.1 million). Consumer news sources and media are trying to get your attention, and usually amplify the hype without necessarily providing much actual insight. Here are a few thoughts to consider, especially when extrapolating to gene therapy or similar for MTM/CNM…
1) Type 1 SMA is an early-onset, relatively rapid progression that irreversibly destroys the motor neurons. After about age 2 the damage is severe, requiring extensive intervention and support and generally fatal over time, though supportive technology such as mechanical ventilation can help, much like with MTM. This gene therapy stops the progression of SMA, but cannot undo damage that has been done. Therefore, the approval today was only for patients under age 2. This underscores the importance of early accurate genetic diagnosis. MTM, in contrast, generally does not destroy the muscle tissue over time. Rather, the missing myotubularin acts a bit like a “key” that unlocks the existing muscle machinery. While it is yet to be proven in human patients, it is hoped that all age ranges would benefit from gene therapy for MTM. Importantly though, there are other long-term effects of lack of muscle strength, such as joint contractures, that may be more challenging to address in older patients even if muscle strength was restored.
2) Novartis has estimated the cost of medical care for someone with SMA to be about $4M for a span of 10 years. From an insurance/payers perspective, the $2.1M “price tag” for the gene therapy should be understood relative to the expected benefits. It is a single-dose treatment, one and done. If administered early enough (aka under 2 years old) it is reasonable to expect that the $4M in costs are avoided, hence a “savings” of about $2M over 10 years. Note – this can start to sound like putting a value on a human life, which is an abhorrent concept, but it really is just about setting a reasonable price for the drug, compared to the costs of alternative care. Steven Pearson, President of the Institute for Clinical and Economic Review (ICER) said, “Insurers were going to cover Zolgensma no matter the price, and Novartis has spoken publicly about considering prices that approached $5 million. It is a positive outcome for patients and the entire health system that Novartis instead chose to price Zolgensma at a level that more fairly aligns with the benefits for these children and their families.”
3) Novartis is offering insurers a payment plan ($425K per year for 5 years), which is an attempt to address the real challenge of how to pay for a treatment like this that is so different from just about any other medical treatment available today. As the field of gene therapy progresses, these types of alternative payment models will be needed, and this is an area of much work for shaping new public policy and legislation. The patient & family voice is needed here as well!
4) The development of a gene therapy product takes several years and many many millions of dollars. The sponsoring company has to foot the bill – often underwritten by investors, private or public, who take on the financial risk given that most drug development efforts never get approved. The first Phase 1 clinical trial for Zolgensma (called AVXS-101 at the time) began in 2014, so that is about 5 years worth of expensive clinical trials and other development, manufacturing, and regulatory activities (not to mention pre-clinical work) without a single penny in sales. Eventually, these development costs need to be paid back by successfully marketing a product. For MTM, Audentes initiated their Phase 1/2 clinical trial “ASPIRO” with the first patient dosed in September 2017, about 1.5 years ago. While each development timeline and approval pathway is unique and we can’t really connect SMA and MTM, it is generally an encouraging sign that the FDA has granted approval for Zolgensma, and that a novel payment approach is being implemented. We can certainly continue to hope that the data published so far for ASPIRO will be reinforced by future positive results, leading to expedited approval and access for all who need it.
As potential treatments for rare diseases such as XLMTM are being developed, it is essential that when and if they are approved for clinical use that they will also be accessible by all the patients that need them. Current pricing and reimbursement models would be a major obstacle, especially for single-dose treatments that have cost hundreds of millions of dollars to develop.
U.S. Senator Bill Cassidy, M.D. (R-LA), and Senator Mark Warner (D-VA) on Jan. 29th released a draft version of the Patient Affordability, Value and Efficiency Act. This bipartisan legislation aims to facilitate new and innovative payment models for pharmaceuticals and other medical services so that patients have better access to treatment, the health care market is more efficient, and drug prices are more affordable.
The Cassidy-Warner proposal increases the ability to move toward value-based payment, which directly connect pricing for prescription drugs and medical devices to their clinical effectiveness.
MTM-CNM Family Connection was pleased to join several patient advocacy groups in signing a letter of support for Cassidy & Warner’s efforts. Read the letter attached below, and the press release at www.cassidy.senate.gov/newsroom/press-releases/cassidy-warner-unveil-draft-legislation-to-lower-drug-prices-through-innovative-payment-models.
With best wishes for 2019 to all of our MTM-CNM community. Hope to see you in St. Louis this July!
Join our Crowdrise campaign for the upcoming conference at https://www.crowdrise.com/o/en/campaign/2019-mtm-cnm-family-conference.
Yesterday, Audentes Therapeutics provided a quarterly company update, including information on their lead program - clinical development of AT132, a gene therapy product targeting X-Linked Myotubular Myopathy (XLMTM). Their Phase 1/2 clinical trial, called "ASPIRO", is well underway, and they state:
"...we have recently completed enrollment of the Cohort 2 dose of 3x1014 vg/kg, including three treated patients and one untreated control patient. We look forward to engaging with the FDA and EMA in the coming weeks to discuss development plans and the potential registration pathway for AT132, and to advance our goal of making this important treatment available to patients living with XLMTM as rapidly as possible."
Additional information in the full press release may be found on the Audentes website here. Also, as has been their practice, Audentes has shared a letter with our community, which can be read here.
Erin Ward, President of MTM-CNM Family Connection, has been serving as a Parent Partner for the Boston Children’s Hospital process design team participating in an Agency for Healthcare Research and Quality-sponsored, Harvard Chan School of Public Health-led Engineering High Reliability Learning Lab, since the program’s inception in 2015. The team’s work has focused on improving the process for complex spine surgery. Today, the team's shared Decision-Making Guide and patient-centered video series has been released by the project’s collaborative partners at Courageous Parents Network. Erin shares more in the blog post below:
In 2014, Will had major spinal surgery and although he rocked the surgery, the process to get there seemed so much more challenging and complex then it should be. Much of the coordination to communicate perioperatively with Will’s multiple specialists was on us, his parents. At the time I had been working with a complex care specialist on another project, and began to share the challenges we experienced. He listened and heard the complexities of the process, and he believed that as a universal care system “we” could do better! Dr. Jay Berry was in the process of applying for a multi-institutional grant, which came to be known as “Engineering High Reliability Learning Labs" (EHRLL). Under this grant, medical entities including our team from Boston Children’s Hospital would collaborate with Harvard’s Chan School of Public Health and Northeastern University’s Health Systems Engineering team to create better care processes using systems engineering principles, aiming to improve the quality of health delivery.
Since 2015, our team has been working to improve the process that patients experience when considering, and undergoing, major spine surgery. There are many learnings that have developed out of this work. Today, the team's shared Decision-Making Guide, that we hope may be helpful for patients and families who are considering spinal surgery, was released by our collaborating partners at Courageous Parents Network (CPN). CPN has also worked with our Boston Children’s Hospital team to develop a series of videos that share conversations about the challenges and considerations of complex spine surgery from the perspectives of a parent, complex care physician, and surgeon. We hope that the conversations captured will allow patients and families facing a potential surgery an opportunity to consider how to go through this complex decision making process. We encourage families to partner with their providers and work to develop a personalized care pathway that will be best for their child and family. Please feel free to share with those that might benefit and also please share any feedback as the shared Decision-Making Guide is a living guide, intended to be updated and modified to best serve families and medical professionals partnering with them to provide optimal care.
MTM-CNM Family Connection's Blog
Sharing information, resources, updates, and thoughts on various topics of interest to the MTM-CNM community.